|
|
Post by BlueCat on Oct 29, 2015 0:02:42 GMT -5
For convenience …. Q3 conference call Oct 29Strategy presentation "Meet Sanofi Management" Nov 6 Not clear to me if the quarterly is effectively being broken into two separate meetings here - October 29 for specifics on Q3 performance only, and Nov 6 for all the forward-looking stuff that normally could have been done on Oct 29, but looks like they just needed more time to go deep. Will be interesting to watch if anything material, or at all, is covered on Afrezza! |
|
|
|
Post by mbseeking on Oct 29, 2015 1:40:24 GMT -5
As I've said elsewhere we have been too benign in our assessment of what SNY is doing. This from that press release above " Accounting for recent market trends, Sanofi now projects global diabetes sales over the period of 2015-2018 to decline at an average annualized rate of between 4% and 8% at CER. Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®, Lyxumia® and BGM (Blood Glucose Monitoring)."
So SNY is slipping because of Afrezza. Really? There is still no insurance coverage, and no published clinical trials by Sanofi to improve that. I guess if you position a product as a niche product then and achieve your goals then this is what happens. Or do we still say SNY know what they are doing ?
|
|
|
|
Post by peppy on Oct 29, 2015 1:45:38 GMT -5
en.sanofi.com/Images/40079_20151029_Q3RESULTS_EN.pdf
Broad-based sales growth despite Diabetes sales erosion in the U.S.
Group sales(2) increased 3.4% (up 9.2% on a reported basis) to €9,591 million
Diabetes sales decreased 6.6%, as a result of lower U.S. sales of Lantus®
Genzyme sales (up 32.7%) showed strong momentum driven by Multiple Sclerosis products
Vaccines sales were up 5.5% mainly driven by Emerging Markets(3)
Animal Health delivered another strong performance (up 9.3%) driven by NexGard®
Emerging Markets sales increased by 11.4%
Steady financial performance taking into account higher investments in new products
Operating expenses were €3,816m, up 7.5% at CER
Business net income grew 5.0% at CER (up 8.3% on a reported basis) to €2,096 million
Business EPS increased 6.1% at CER to €1.61 and grew 9.5% on a reported basis
Subsequent event - The financial impact of a voluntary recall announced yesterday for Auvi-
Q® and Allerject® in the U.S. and Canada is under evaluation and will be accounted for in Q4
2015. An initial estimate is a negative impact of approximately €100m on Business Net
Income
Significant progress in advancing innovative products
Praluent® launched in the U.S. in July and first EU launches underway
New Drug Application for lixisenatide accepted for review by the FDA
Primary endpoint met in second Phase III study for LixiLan in Type 2 diabetes
2015-2018 Diabetes outlook
Accounting for recent market trends, Sanofi now projects global diabetes sales over the period
of 2015-2018 to decline at an average annualized rate of between 4% and 8% at CER. Sanofi
will mitigate the impact of this revised sales expectation on its business operating income by
2018 and will present the mid-term strategic and financial outlook for the Group on November
6, 2015
screencast.com/t/7urp6XBMfYB8 screencast.com/t/zIphYqlThpq1
In the third quarter, sales of the Diabetes division decreased 6.6% to €1,852 million, reflecting lower
sales of Lantus® in the U.S. In the U.S., sales of Diabetes were €1,075 million (down 16.4%). Sales of
Diabetes outside the U.S. were €777 million, an increase of 8.1%. Strong performance in Emerging
Markets (€373m, up 15.5%) was moderated by stable sales in Western Europe (€296m, down 0.3%),
largely attributable to the entry of glargine biosimilar competition. Year-to-date sales for the Diabetes
division were €5,677 million down 4.6%.
Given recent sales trends for the diabetes business and ongoing market dynamics, Sanofi now
expects its global diabetes sales to be down between 6% to 7% at CER for 2015. Accounting for
recent market trends, Sanofi now projects global diabetes sales over the period of 2015-2018 to
decline at an average annualized rate of between 4% and 8% at CER. Approximately half of this
revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®,
Lyxumia® and BGM (Blood Glucose Monitoring). Sanofi will mitigate the impact of this revised sales
expectation on its business operating income by 2018 and will present the mid-term strategic and
financial outlook for the Group on November 6, 2015.
Afrezza® sales were €2 million and €5
million in the third quarter and the first nine months of 2015, respectively.
(Express Scripts to add
Praluent® in a branded preferred Tier 2 formulary position. Sales of Praluent® were €4 million in Q3)
|
|
|
|
Post by fedakd on Oct 29, 2015 1:48:37 GMT -5
No accountability at Sanofi whatsoever. The fact they are passing the buck with Afrezza shows how pathetic they truly are. Most diabetics don't even know about the drug, let alone there being the T2 insurance coverage issue. Absolutely mind boggling stuff here.
|
|
|
|
Post by jpg on Oct 29, 2015 1:51:45 GMT -5
As I've said elsewhere we have been too benign in our assessment of what SNY is doing. This from that press release above " Accounting for recent market trends, Sanofi now projects global diabetes sales over the period of 2015-2018 to decline at an average annualized rate of between 4% and 8% at CER. Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®, Lyxumia® and BGM (Blood Glucose Monitoring)." So SNY is slipping because of Afrezza. Really? There is still no insurance coverage. I guess if you position a product as a niche product then and achieve your goals then this is what happens. No they are saying: Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®, Lyxumia® and BGM (Blood Glucose Monitoring). They are not blaming Afrezza but stating an obvious fact for approximately half linked to ... Not everything is about Afrezza! I'm not saying Sanofi is a great partner (I so would have loved Novartis) but hopefully they will try doing something more than accept their faith of decline! |
|
|
|
Post by ezmit on Oct 29, 2015 1:52:11 GMT -5
So 5 Million euro on the year so far.. Maybe i'm being impatient but I just feel like Sanofi is doing about as minimal effort as it can.
|
|
|
|
Post by mbseeking on Oct 29, 2015 1:59:18 GMT -5
As I've said elsewhere we have been too benign in our assessment of what SNY is doing. This from that press release above " Accounting for recent market trends, Sanofi now projects global diabetes sales over the period of 2015-2018 to decline at an average annualized rate of between 4% and 8% at CER. Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®, Lyxumia® and BGM (Blood Glucose Monitoring)." So SNY is slipping because of Afrezza. Really? There is still no insurance coverage. I guess if you position a product as a niche product then and achieve your goals then this is what happens. No they are saying: Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®, Lyxumia® and BGM (Blood Glucose Monitoring). They are not blaming Afrezza but stating an obvious fact for approximately half linked to ... Not everything is about Afrezza! I respectfully disagree. This is code for French people running for the hills. This is the first time we've seen Afrezza mentioned officially by SNY since Brandicourt took over. Its negative. That they could be booking a miss in future earnings without having once addressed the levers they are supposed to pull (advertising , trials , insurance coverage) is as one other poster points out : a lack of accountability. |
|
|
|
Post by ezmit on Oct 29, 2015 2:00:14 GMT -5
<script type="text/javascript" src="//www.google.com/trends/embed.js?hl=en-US&q=afrezza,+exubera&cmpt=q&tz=Etc/GMT%2B7&tz=Etc/GMT%2B7&content=1&cid=TIMESERIES_GRAPH_0&export=5&w=500&h=330"></script>
Pretty much all that needs to be said. Afrezza has 0 awareness. Imagine sales without the help of Sam and some of the others on twitter.
|
|
|
|
Post by peppy on Oct 29, 2015 2:10:49 GMT -5
No they are saying: Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza®, Lyxumia® and BGM (Blood Glucose Monitoring). They are not blaming Afrezza but stating an obvious fact for approximately half linked to ... Not everything is about Afrezza! I respectfully disagree. This is code for French people running for the hills. This is the first time we've seen Afrezza mentioned officially by SNY since Brandicourt took over. Its negative. That they could be booking a miss in future earnings without having once addressed the levers they are supposed to pull (advertising , trials , insurance coverage) is as one other poster points out : a lack of accountability. The code was changed. Praluent in a trial with Afrezza. (that ends in 2017) Including Praluent®sales of €4 million in Q3 2015(5) |
|
|
|
Post by lakemann on Oct 29, 2015 5:05:26 GMT -5
Well, it may not be doing the best at this time,BUT, it don't look like their backing out of the deal with MNKD.. So maybe they will change their strategy with affezza.. Looks like we are still in wait and see mode..
|
|
|
|
Post by falconquest on Oct 29, 2015 5:24:34 GMT -5
Their expectations are low? Well, hello! This statement is completely inexcusable to me. You don't lower expectations for your diabetes unit while sitting on the finest diabetes treatment to be developed.....ever. I am just so disillusioned with this company. At every turn we run into roadblocks. Sanofi doesn't deserve to have this. We need a real player who can market Afrezza. If something doesn't happen soon, I'm out. I have sold a portion of my position already and will sell the rest soon if we don't get something going. I'm not going to sit around another 5-10 years waiting for someone to figure this out!
|
|
|
|
Post by ashiwi on Oct 29, 2015 5:36:13 GMT -5
This is what bothers me. Why is Praluent Sanofi's golden child ?
Jérôme Contamine: As you know, Praluent® received U.S. approval in late July and EU approval in late September. The product was launched in the U.S. within days and is gaining market access and developing awareness in the broader medical community. It will become available in some major European countries by year end.
Our comprehensive patient and prescriber support hub, called “MyPraluent”, has already served as an effective platform for over 4,000 prescribers. We recently secured branded preferred Tier 2 commercial formulary position with Express Scripts. In addition to gaining greater U.S. market access, near-term expansion opportunities are focused on driving product awareness and adoption. We are also pleased to report that launches in the first European countries are underway.
So overall, launch progress is consistent with our expectations of a gradual uptake in the market.
|
|
|
|
Post by lakemann on Oct 29, 2015 5:37:30 GMT -5
Nov 6 will tell more as to what their going to do . Says their going to mitigate this forecast ..
|
|
|
|
Post by falconquest on Oct 29, 2015 6:02:07 GMT -5
Nov 6 will tell more as to what their going to do . Says their going to mitigate this forecast .. Then it isn't much of a forecast is it? |
|
|
|
Post by lakemann on Oct 29, 2015 6:18:27 GMT -5
Nope not much but at least they told their shareholders where affezza stands at the current point.. And on nov 6 will explain what their going to do about it.. That's how I read it.
|
|
